Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2011

SAN FRANCISCO, March 1, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the 31st Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 8, 2011 at 11:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2011.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 late-stage development program to treat opioid-induced constipation and its NKTR-119 earlier stage development program for the treatment of pain without constipation side effects.  NKTR-181 is a novel mu-opioid analgesic molecule that is being prepared for Phase 1 clinical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in S
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
4. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
5. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
7. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
10. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
11. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Leaving the car ... public transit is good for your health, a new study ... United Kingdom and found that 76 percent of men and ... men and 11 percent of women used public transit, and ... or walked. Those who drove to work weighed more ...
(Date:8/20/2014)... According to a new market ... SPD, Liquid Crystal, Microblinds, Thermographic and Photochromics), by ... others), by geography - Global Forecast to 2014 ... Smart glass market was worth $1581.4 Million in ... by 2020, at an estimated CAGR of 20% ...
(Date:8/20/2014)... Raleigh, NC (PRWEB) August 20, 2014 Doctors ... a way to wipe out mesothelioma in laboratory mice by ... Mesothelioma has just posted details of the study on its ... , Scientists with Hong Kong University’s AIDS Institute of ... death protein 1” or PD-1. By altering DNA, the vaccine ...
(Date:8/20/2014)... New Jersey’s Medical Marijuana Program has ... tens of thousands of patients in the state. However, ... that would expand the list of qualifying conditions and ... summer by State Assemblywoman Linda Stender, the need to ... growing. , To help fill the information gap for ...
(Date:8/20/2014)... OR (PRWEB) August 20, 2014 August ... are urged to become educated about eye health and ... examined. One frequently overlooked eye condition that must be ... Sharon Kleyne Hour Power of Water radio show, is ... children increasing exponentially, childhood dry eye is becoming a ...
Breaking Medicine News(10 mins):Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3
... painkillers to treat inflammation are linked to an increased ... or flutter), concludes a study published on bmj.com ... drugs (NSAIDS) as well as new generation anti-inflammatory drugs, ... already been linked to an increased risk of heart ...
... Dennis Thompson HealthDay Reporter , SUNDAY, July 3 (HealthDay ... the summer air with dazzling colors and deafening sounds. But they ... year are harmed by fireworks, many of them maimed for life, ... care. "Where we see injuries is a lack of common ...
... N.C. July 4, 2011 Smoking cigarettes is a ... the smokers who choose to use one of the most ... the risk of serious cardiovascular events are on their way. ... Baptist Medical Center, in collaboration with researchers at Johns Hopkins ...
... Reinberg HealthDay Reporter , FRIDAY, July 1 (HealthDay ... are endorsing a U.S. health advisory panel,s recommendation that the ... breast cancer. The reason: There,s still a lack of ... Avastin was given fast-track approval by the U.S. ...
... The children most likely to walk or cycle to ... in an economically disadvantaged home, according to survey results that ... Pabayo of the University of Montreal Hospital Research Centre and ... is unique in that it follows the same group of ...
... the international aid community started to fund health programs ... support for tackling infectious diseases, and for implementing immunization ... and by governments are not always the same. New ... Globalization and Health uses ,agency theory, to examine ...
Cached Medicine News:Health News:Common painkillers linked to irregular heart rhythm 2Health News:Safety Experts Warn of Fireworks Dangers 2Health News:Safety Experts Warn of Fireworks Dangers 3Health News:Safety Experts Warn of Fireworks Dangers 4Health News:Chantix associated with 72 percent increased risk of serious CV events 2Health News: Avastin Rejection Supported by Cancer Experts 2Health News: Avastin Rejection Supported by Cancer Experts 3Health News: Avastin Rejection Supported by Cancer Experts 4Health News:Urban children are healthier commuters than rural teens 2Health News:Getting aid to where it is needed 2
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... Medicine Knot Pusher is a reusable instrument used ... Knot Pusher is utilized in the handling and ... two piece shaft allows the surgeon to place ... pushing. The ring handle allows the surgeon ease ...
Medicine Products: